touchIMMUNOLOGY caught up with Jonathan Bernstein (University of Cincinnati; Bernstein Allergy Group, Bernstein Clinical Research Center, Cincinnati, OH, USA) to discuss the prevalence of hereditary angioedema, lanadelumab as a treatment option, and the current challenges faced by patients.
The abstract ‘Efficacy of Lanadelumab in Hereditary Angioedema Patients With and Without Prior Use of Long-Term Prophylaxis: Final Results From the HELP Open-Label Extension Study.’ (ABSTRACT NUMBER: 462) was presented at the American Academy of Allergy, Asthma & Immunology Virtual Annual Meeting, February 26-March 1, 2021.
Questions:
- Could you give us a brief overview of hereditary angioedema (HAE), its prevalence and pathogenesis? (0:20)
- Where does lanadelumab sit in the current treatment paradigm for the prevention of HAE attacks? (2:05)
- What are the challenges in individualised prescribing of lanadelumab for the prevention of HAE attacks? (3:50)
Disclosures: Jonathan Bernstein has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AAAAI 2021 (Virtual).
